BioCentury
ARTICLE | Clinical News

Cometriq cabozantinib: Phase III data

July 27, 2015 7:00 AM UTC

Top-line data from the first 375 randomized patients in the open-label, international Phase III METEOR trial in 658 patients who progressed after >=1 VEGF receptor tyrosine kinase inhibitor (TKI) show...